By Fineline Cube 
Johnson & Johnson (J&J, NYSE: JNJ) released 52-week long-term data from the Phase III ICONIC-ADVANCE 1/2 and ICONIC-LEAD trials, demonstrating that Icotyde™ (icotrokinra)—the world’s first and only targeted oral peptide blocking the IL-23 receptor—achieved sustained and improving complete skin clearance (PASI 100) in adults with moderate-to-severe plaque psoriasis (PsO). Patients on continuous Icotyde saw PASI 100 rates rise from 41% to 49% (ADVANCE 1) and 33% to 48% (ADVANCE 2) between Weeks 24 and 52. Those who switched from placebo to Icotyde at Week 16 reached comparable clearance rates by Week 52, reinforcing the drug’s durability and reversibility of delay. Critically, Icotyde showed a favorable safety profile through 52 weeks, with lower overall adverse event and infection rates versus deucravacitinib at Week 24.
Long-Term Efficacy Highlights (Week 52)
| Study Arm | PASI 100 at Week 24 | PASI 100 at Week 52 | Trend |
|---|---|---|---|
| Icotyde (ADVANCE 1) | 41% | 49% | ↑ +8 ppt |
| Icotyde (ADVANCE 2) | 33% | 48% | ↑ +15 ppt |
| Placebo → Icotyde (switch at W16) | — | 50% (ADV1) / 43% (ADV2) | Matches continuous therapy |
The continued improvement beyond 24 weeks suggests progressive tissue remodeling and immune normalization—a hallmark of deep IL-23 pathway inhibition.
Safety Profile Advantage
| Metric (Through Week 24) | Icotyde | Deucravacitinib |
|---|---|---|
| Overall Adverse Events | Lower | Higher |
| Infection Rates | Lower | Higher |
| New Safety Signals (through W52) | None identified | — |
With no new safety signals emerging through one full year, Icotyde reinforces its potential as a best-in-class oral IL-23–targeted therapy, distinct from small-molecule TYK2 inhibitors.
Drug Profile & Mechanism
- Class: Oral peptide therapeutic (first of its kind in immunology)
- Target: IL-23 receptor—blocked with high precision, preventing downstream Th17 activation
- Differentiation: Unlike TYK2 inhibitors (e.g., deucravacitinib) that indirectly modulate IL-23 signaling, Icotyde directly inhibits the receptor, offering potentially greater specificity and fewer off-target effects
- Origin: Discovered by Protagonist Therapeutics, co-developed under global licensing agreement with J&J
J&J holds exclusive rights to Phase II+ development and global commercialization across multiple indications, including psoriasis, psoriatic arthritis, and inflammatory bowel disease.
Strategic Implications
- Paradigm Shift: Validates oral peptides as viable alternatives to injectable biologics in chronic autoimmune disease
- Competitive Edge: Combines biologic-like efficacy (PASI 100 ~50%) with oral convenience and enhanced safety
- Pipeline Expansion: Success in PsO paves the way for trials in Crohn’s disease and ulcerative colitis, where IL-23 is equally central
If approved, Icotyde could capture significant share from both injectable IL-23 mAbs (e.g., guselkumab, risankizumab) and oral TYK2 inhibitors, particularly among patients seeking complete clearance without injection burden.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and competitive positioning. Actual outcomes may vary due to FDA/EMA review, long-term safety monitoring, and market adoption dynamics.-Fineline Info & Tech